RT @ericdeinmd: #ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19. â¶ï¸150
Tweet Content
#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19.
▶️150 mg RZB vs Placebo
⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI
⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn
⭐️No safety signal
https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off